Isbn: 9783031671128 - dose finding and beyond in biopharmaceutical development (4 risultati)

Perfeziona la tua ricerca

  • Libri (4)

  • Nuovo (4)

a

Fascia di prezzo personalizzata (EUR)

a

    • Lingua: Inglese

      Editore: Springer, 2025

      3031671120 / 9783031671128

      • Brossura

      Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 179,29

      EUR 30,50 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 1 disponibili

      Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - This book covers topics in 2 parts: 1) Review of FDA Guidance, 2) Novel Designs and Analyses. While covering basic principles of dose finding, this book details advancements made in drug development.Finding the right dose(s) is one of the most important objectives in new drug development. In Phase I clinical development, one of the objectives is to escalate test doses from low to high. The low doses should be safe, then escalate up to the maximally tolerable dose (MTD). Phase clinical trials then lower test doses to the minimal efficacious dose (MinED). Dose range of a study drug can be thought of as the doses between MinED and MTD. From this dose range, one or a few doses are selected for Phase confirmation. In practice, dose finding is a very difficult in every phase of clinical development for new drugs.The editors brought distinguished researchers and practitioners in biopharmaceuticals and universities, to discuss the statistical procedures, useful methods, and their novel applications in dose finding. The chapters in the book present emerging topics in dose-finding and related interdisciplinary areas. This timely book is a valuable resource to stimulate the development of this growing and exciting field in drug development.

    • Lingua: Inglese

      Editore: Springer, 2025

      3031671120 / 9783031671128

      • Brossura

      Da: preigu, Osnabrück, Germaniapreigu

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 149,10

      EUR 70,00 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 5 disponibili

      Taschenbuch. Condizione: Neu. Dose Finding and Beyond in Biopharmaceutical Development | Jingjing Ye (u. a.) | Taschenbuch | ICSA Book Series in Statistics | xvii | Englisch | 2025 | Springer | EAN 9783031671128 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

    • Lingua: Inglese

      Editore: Springer Okt 2025, 2025

      3031671120 / 9783031671128

      • Brossura
      • Print on Demand

      Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 171,19

      EUR 23,00 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 2 disponibili

      Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book covers topics in 2 parts: 1) Review of FDA Guidance, 2) Novel Designs and Analyses. While covering basic principles of dose finding, this book details advancements made in drug development.Finding the right dose(s) is one of the most important objectives in new drug development. In Phase I clinical development, one of the objectives is to escalate test doses from low to high. The low doses should be safe, then escalate up to the maximally tolerable dose (MTD). Phase clinical trials then lower test doses to the minimal efficacious dose (MinED). Dose range of a study drug can be thought of as the doses between MinED and MTD. From this dose range, one or a few doses are selected for Phase confirmation. In practice, dose finding is a very difficult in every phase of clinical development for new drugs.The editors brought distinguished researchers and practitioners in biopharmaceuticals and universities, to discuss the statistical procedures, useful methods, and their novel applications in dose finding. The chapters in the book present emerging topics in dose-finding and related interdisciplinary areas. This timely book is a valuable resource to stimulate the development of this growing and exciting field in drug development. 272 pp. Englisch.

    • Lingua: Inglese

      Editore: Springer Okt 2025, 2025

      3031671120 / 9783031671128

      • Brossura
      • Print on Demand

      Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germaniabuchversandmimpf2000

      Venditore con 5 stelle
      Contatta il venditore

      Condizione: Nuovo

      EUR 171,19

      EUR 60,00 spedizione 
      Spedito da Germania a U.S.A.

      Quantità: 1 disponibili

      Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -This book covers topics in 2 parts: 1) Review of FDA Guidance, 2) Novel Designs and Analyses. While covering basic principles of dose finding, this book details advancements made in drug development.Finding the right dose(s) is one of the most important objectives in new drug development. In Phase I clinical development, one of the objectives is to escalate test doses from low to high. The low doses should be safe, then escalate up to the maximally tolerable dose (MTD). Phase ¿ clinical trials then lower test doses to the minimal efficacious dose (MinED). Dose range of a study drug can be thought of as the doses between MinED and MTD. From this dose range, one or a few doses are selected for Phase ¿ confirmation. In practice, dose finding is a very difficult in every phase of clinical development for new drugs.The editors brought distinguished researchers and practitioners in biopharmaceuticals and universities, to discuss the statistical procedures, useful methods, and their novel applications in dose finding. The chapters in the book present emerging topics in dose-finding and related interdisciplinary areas. This timely book is a valuable resource to stimulate the development of this growing and exciting field in drug development. 272 pp. Englisch.